NPC
MCID: NSP012
MIFTS: 65

Nasopharyngeal Carcinoma (NPC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Nasopharyngeal Carcinoma

MalaCards integrated aliases for Nasopharyngeal Carcinoma:

Name: Nasopharyngeal Carcinoma 57 12 76 53 59 29 55 6 15 40 73
Nasopharyngeal Cancer 57 53 37
Malignant Neoplasm of Nasopharynx 12 73
Nasopharyngeal Carcinoma 1 57 13
Nasopharyngeal Neoplasms 44 73
Nasopharynx Carcinoma 12 15
Malignant Neoplasm of Other Specified Sites of Nasopharynx 12
Primary Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Posterior Wall of Nasopharynx 12
Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Superior Wall of Nasopharynx 12
Malignant Neoplasm of Lateral Wall of Nasopharynx 12
Malignant Tumor of Posterior Wall of Nasopharynx 12
Malignant Tumor of Anterior Wall of Nasopharynx 12
Malignant Tumor of Lateral Wall of Nasopharynx 12
Squamous Cell Carcinoma of the Nasopharynx 59
Malignant Neoplasm of Nasopharyngeal Wall 12
Malignant Neoplasm of Roof of Nasopharynx 12
Malignant Nasopharyngeal Tumor 12
Carcinoma of Nasopharynx 12
Cancer of Nasopharynx 73
Nasopharynx Cancer 12
Npca 57
Npc 57

Characteristics:

Orphanet epidemiological data:

59
nasopharyngeal carcinoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

HPO:

32
nasopharyngeal carcinoma:
Inheritance polygenic inheritance


Classifications:

Orphanet: 59  
Rare respiratory diseases


External Ids:

OMIM 57 607107
Disease Ontology 12 DOID:9261
MeSH 44 D009303
NCIt 50 C9321
Orphanet 59 ORPHA150
UMLS via Orphanet 74 C0238301 C2931822 C0153392
MESH via Orphanet 45 C538339
ICD10 via Orphanet 34 C11.0 C11.1 C11.2 more
MedGen 42 C2931822
KEGG 37 H00054
SNOMED-CT via HPO 69 126680004

Summaries for Nasopharyngeal Carcinoma

OMIM : 57 Nasopharyngeal carcinoma (NPC, NPCA) is a multifactorial malignancy associated with both genetic and environmental factors. The cancer arises from the epithelium of the nasopharynx. The Epstein-Barr virus has been implicated (Tse et al., 2009). (607107)

MalaCards based summary : Nasopharyngeal Carcinoma, also known as nasopharyngeal cancer, is related to squamous cell carcinoma and leukemia, and has symptoms including headache, tinnitus and rhinorrhea. An important gene associated with Nasopharyngeal Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Cisplatin and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include lymph node, endothelial and t cells, and related phenotype is neoplasia of the nasopharynx.

Disease Ontology : 12 A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or \

Wikipedia : 76 Nasopharynx cancer or nasopharyngeal carcinoma (NPC) is the most common cancer originating in the... more...

Related Diseases for Nasopharyngeal Carcinoma

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 2 Nasopharyngeal Carcinoma 3

Diseases related to Nasopharyngeal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 316)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 30.7 CDKN2B-AS1 FOXCUT H19 HOTAIR HRAS MALAT1
2 leukemia 30.5 CDKN2B-AS1 HOTAIR NEAT1 NRAS TP53
3 adenocarcinoma 30.4 H19 HRAS MALAT1 PIK3CA TP53
4 tongue squamous cell carcinoma 30.2 AFAP1-AS1 MALAT1 TP53
5 acute lymphocytic leukemia 30.1 CDKN2B-AS1 TP53 XIST
6 squamous cell carcinoma, head and neck 30.1 H19 HOTAIR HRAS MIR29C PIK3CA TP53
7 renal cell carcinoma, nonpapillary 30.1 H19 HOTAIR MALAT1 NPTN-IT1
8 laryngeal squamous cell carcinoma 30.1 CDKN2B-AS1 H19 HOTAIR MALAT1 NEAT1 TP53
9 esophageal cancer 30.0 CDKN2B-AS1 FOXD2-AS1 H19 HOTAIR HRAS MALAT1
10 prostate cancer 30.0 CDKN2B-AS1 H19 HOTAIR HRAS MALAT1 MIR100
11 breast cancer 29.9 CDKN2B-AS1 FOXCUT H19 HOTAIR HRAS MALAT1
12 melanoma 29.9 CDKN2B-AS1 H19 HOTAIR MALAT1 MIR100 NRAS
13 lung cancer 29.7 AFAP1-AS1 CDKN2B-AS1 FOXD2-AS1 H19 HOTAIR HRAS
14 nasopharyngeal carcinoma 3 12.5
15 nasopharyngeal carcinoma 2 12.5
16 nasopharyngeal cancer, childhood 12.1
17 niemann-pick disease, type c1 11.8
18 lymphoepithelioma-like carcinoma 11.5
19 niemann-pick disease, type c2 11.1
20 serous cystadenocarcinoma 10.4 HRAS PIK3CA TP53
21 cystadenocarcinoma 10.4 HRAS PIK3CA TP53
22 ovary adenocarcinoma 10.4 HRAS PIK3CA TP53
23 adult hepatocellular carcinoma 10.4 PIK3CA TP53
24 skin squamous cell carcinoma 10.4 HRAS PIK3CA TP53
25 malignant ovarian surface epithelial-stromal neoplasm 10.4 HRAS PIK3CA TP53
26 rare adenocarcinoma of the breast 10.4 PIK3CA TP53
27 ovary epithelial cancer 10.4 HRAS PIK3CA TP53
28 respiratory system cancer 10.4 HRAS MALAT1 PIK3CA TP53
29 carcinosarcoma 10.4 HRAS PIK3CA TP53
30 malignant spiradenoma 10.4 PIK3CA TP53
31 apocrine adenoma 10.4 HRAS PIK3CA
32 uterine carcinosarcoma 10.4 HRAS PIK3CA TP53
33 prostate adenoid cystic carcinoma 10.4 HRAS PIK3CA
34 intestinal disease 10.4 HRAS PIK3CA TP53
35 small cell cancer of the lung 10.4 HOTAIR MALAT1 PIK3CA TP53
36 triple-receptor negative breast cancer 10.4 HOTAIR MALAT1
37 prostate disease 10.4 CDKN2B-AS1 H19 MALAT1 TP53
38 esophagus squamous cell carcinoma 10.4 AFAP1-AS1 HOTAIR
39 suppression of tumorigenicity 12 10.4 HRAS PIK3CA TP53
40 ovarian epithelial cancer 10.4 H19 HOTAIR MALAT1 PIK3CA
41 kidney cancer 10.4 H19 HOTAIR MALAT1 MIR29C TP53
42 spitz nevus 10.4 HRAS TP53
43 lung squamous cell carcinoma 10.4 HRAS NPTN-IT1 PIK3CA TP53
44 gastrointestinal system cancer 10.4 H19 HOTAIR HRAS MALAT1 PIK3CA TP53
45 pituitary adenoma 10.4 H19 HOTAIR MALAT1
46 meningeal melanomatosis 10.4 HRAS NRAS TP53
47 marek disease 10.4 H19 TP53
48 melanomatosis 10.4 HRAS NRAS
49 ovarian serous cystadenocarcinoma 10.4 HRAS NRAS PIK3CA TP53
50 liver angiosarcoma 10.4 HRAS NRAS TP53

Comorbidity relations with Nasopharyngeal Carcinoma via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Nasopharyngeal Carcinoma:



Diseases related to Nasopharyngeal Carcinoma

Symptoms & Phenotypes for Nasopharyngeal Carcinoma

Clinical features from OMIM:

607107

Human phenotypes related to Nasopharyngeal Carcinoma:

32
# Description HPO Frequency HPO Source Accession
1 neoplasia of the nasopharynx 32 HP:0100630

UMLS symptoms related to Nasopharyngeal Carcinoma:


headache, tinnitus, rhinorrhea

Drugs & Therapeutics for Nasopharyngeal Carcinoma

Drugs for Nasopharyngeal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 350)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
2
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
3
Dopamine Approved Phase 4,Phase 2,Early Phase 1 51-61-6, 62-31-7 681
4
Bupropion Approved Phase 4,Phase 2,Early Phase 1 34841-39-9, 34911-55-2 444
5
Nicotine Approved Phase 4,Early Phase 1,Not Applicable 54-11-5 942 89594
6 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
7 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Early Phase 1
9 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Autonomic Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
13 Antidepressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
14 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Early Phase 1
15 Dopamine Uptake Inhibitors Phase 4,Phase 2,Early Phase 1
16 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Early Phase 1
17 Dopamine Agents Phase 4,Phase 2,Early Phase 1
18 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2,Early Phase 1
19 Nicotinic Agonists Phase 4,Early Phase 1,Not Applicable
20 Cholinergic Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
21 Central Nervous System Stimulants Phase 4,Phase 3,Early Phase 1,Not Applicable
22
Celecoxib Approved, Investigational Phase 3,Phase 2,Phase 1 169590-42-5 2662
23
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
24
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
25
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
26
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
27
Aprepitant Approved, Investigational Phase 3,Phase 2 170729-80-3 6918365 151165
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
29
Fosaprepitant Approved Phase 3,Phase 2 172673-20-0 219090
30
Palonosetron Approved, Investigational Phase 3,Phase 2 119904-90-4, 135729-61-2, 135729-56-5 148211
31
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
32
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
33
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
34
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
35
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
36
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
37
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
38
Cetuximab Approved Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
39
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
40
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
41
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
42
Amifostine Approved, Investigational Phase 3,Phase 1,Phase 2 20537-88-6 2141
43
Acyclovir Approved Phase 3 59277-89-3 2022
44
Oprelvekin Approved, Investigational Phase 3 145941-26-0
45
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
46
Methotrexate Approved Phase 3,Phase 2 59-05-2, 1959-05-2 126941
47
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
48
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
49
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
50
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 587)
# Name Status NCT ID Phase Drugs
1 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Unknown status NCT02293356 Phase 4 Nimotuzumab Injection
2 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Active, not recruiting NCT02948699 Phase 4
3 Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury Recruiting NCT03069820 Phase 4 docetaxel and cisplatin
4 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
5 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
6 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
7 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
8 The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
9 The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT Unknown status NCT01817023 Phase 3 Cisplatin
10 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
11 A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
12 Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01245959 Phase 3 Docetaxel, cisplatin and fluorouracil
13 Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT02944708 Phase 3 Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2
14 Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
15 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
16 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
17 EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients Unknown status NCT03006588 Phase 2, Phase 3
18 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
19 Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma Unknown status NCT01528618 Phase 3 gemcitabine and cisplatin;5-Fluorouracil and cisplatin
20 Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
21 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
22 Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC). Unknown status NCT02012062 Phase 3 TPF neoadjuvant chemotherapy;Concurrent chemotherapy with cisplatin during radiotherapy;Concurrent nimotuzumab during radiotherapy
23 PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE. Unknown status NCT00180973 Phase 3 Hydroxyurea
24 Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx Unknown status NCT00003637 Phase 3 cisplatin;fluorouracil
25 Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Unknown status NCT02933099 Phase 3 Aprepitant+palonosetron+dexamethasone;palonosetron+dexamethasone
26 A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02444949 Phase 3 endostar;cisplatin
27 Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
28 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
29 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
30 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
31 Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma Recruiting NCT03321539 Phase 3 CCRT+GP;CCRT+PF
32 TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma Recruiting NCT03306121 Phase 3 TPF+CCRT;CCRT+ PF
33 TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma Recruiting NCT02940925 Phase 3
34 IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma Not yet recruiting NCT03068936 Phase 3 Cisplatin
35 Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
36 Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma Not yet recruiting NCT02907710 Phase 3 Endostar;DDP
37 Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Active, not recruiting NCT02958111 Phase 3 Capecitabine
38 Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma Recruiting NCT02460419 Phase 3 capecitabine
39 Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma Recruiting NCT03707509 Phase 3 Camrelizumab;Placebos;Gemcitabine;Cisplatin
40 Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma Recruiting NCT02111460 Phase 3
41 Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma Recruiting NCT03015727 Phase 3 Docetaxel;Cisplatin;Chemotherapy
42 Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Active, not recruiting NCT01872962 Phase 3 gemcitabine and cisplatin (Induction chemotherapy)
43 Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma Not yet recruiting NCT02786641 Phase 3 Docetaxel;Cisplatin 1;Xeloda;Cisplatin 2
44 A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients Recruiting NCT02578641 Phase 3 combination IV gemcitabine and IV carboplatin (AUC2)
45 Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage Recruiting NCT03403829 Phase 3 Gemcitabine
46 Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma Recruiting NCT03601975 Phase 3 Gemcitabine/Cisplatin
47 A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma Recruiting NCT02512315 Phase 3 Docetaxel (DOC);Cisplatin (DDP)
48 Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial Active, not recruiting NCT02143388 Phase 2, Phase 3 IMRT combine with cisplatin concurrent chemotherapy;IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
49 Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma Not yet recruiting NCT03344068 Phase 2, Phase 3 Chemotherapy
50 Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma Recruiting NCT02610010 Phase 3 Cisplatin

Search NIH Clinical Center for Nasopharyngeal Carcinoma

Cochrane evidence based reviews: nasopharyngeal neoplasms

Genetic Tests for Nasopharyngeal Carcinoma

Genetic tests related to Nasopharyngeal Carcinoma:

# Genetic test Affiliating Genes
1 Nasopharyngeal Carcinoma 29 TP53

Anatomical Context for Nasopharyngeal Carcinoma

MalaCards organs/tissues related to Nasopharyngeal Carcinoma:

41
Lymph Node, Endothelial, T Cells, Bone, Skin, Liver, Lung

Publications for Nasopharyngeal Carcinoma

Articles related to Nasopharyngeal Carcinoma:

(show top 50) (show all 3787)
# Title Authors Year
1
Placenta specific 8 gene induces epithelial-mesenchymal transition of nasopharyngeal carcinoma cells via the TGF-β/Smad pathway. ( 30496758 )
2019
2
PP-22 promotes autophagy and apoptosis in the nasopharyngeal carcinoma cell line CNE-2 by inducing endoplasmic reticulum stress, downregulating STAT3 signaling, and modulating the MAPK pathway. ( 30191969 )
2019
3
Survival differences in nasopharyngeal carcinoma among racial and ethnic minority groups in the United States: A retrospective cohort study. ( 30216675 )
2019
4
Long non-coding RNA 319 facilitates nasopharyngeal carcinoma carcinogenesis through regulation of miR-1207-5p/KLF12 axis. ( 30243935 )
2019
5
Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinoma. ( 30318742 )
2019
6
CircHIPK3 promotes proliferation and invasion in nasopharyngeal carcinoma by abrogating miR-4288-induced ELF3 inhibition. ( 30070690 )
2019
7
Early diagnosis of radio-insensitive human nasopharyngeal carcinoma xenograft models by diffusion kurtosis imaging. ( 30098385 )
2019
8
Fibronectin promotes nasopharyngeal cancer cell motility and proliferation. ( 30551431 )
2019
9
Dosimetric Comparisons of Volumetric Modulated Arc Therapy and Tomotherapy for Early T-Stage Nasopharyngeal Carcinoma. ( 29967769 )
2018
10
A study on the value of narrow-band imaging (NBI) for the general investigation of a high-risk population of nasopharyngeal carcinoma (NPC). ( 29973209 )
2018
11
A Case of Neurotrophic Keratopathy Associated with Nasopharyngeal Carcinoma. ( 29643792 )
2018
12
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. ( 29266526 )
2018
13
Long non-coding RNA n326322 promotes the proliferation and invasion in nasopharyngeal carcinoma. ( 29416735 )
2018
14
Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma carcinogenesis by modulating miR-363-5p/S100A1 pathway. ( 29248577 )
2018
15
Reduced QSOX1 enhances radioresistance in nasopharyngeal carcinoma. ( 29423042 )
2018
16
Lack of association between the distribution of ABO blood groups and nasopharyngeal carcinoma in a population of Southern China. ( 29970653 )
2018
17
miR-93 enhances cell proliferation by directly targeting CDKN1A in nasopharyngeal carcinoma. ( 29434867 )
2018
18
Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma. ( 29971780 )
2018
19
High COX-2 expression contributes to a poor prognosis through the inhibition of chemotherapy-induced senescence in nasopharyngeal carcinoma. ( 29956730 )
2018
20
Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population. ( 29451951 )
2018
21
Downregulation of ribophorin II suppresses tumor growth, migration, and invasion of nasopharyngeal carcinoma. ( 29942140 )
2018
22
Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. ( 29428165 )
2018
23
A regulatory mutant on TRIM26 conferring the risk of nasopharyngeal carcinoma by inducing low immune response. ( 29956500 )
2018
24
Promoter hypermethylation of SLIT2 is a risk factor and potential diagnostic biomarker for nasopharyngeal carcinoma. ( 29107007 )
2018
25
LncRNA THOR attenuates cisplatin sensitivity of nasopharyngeal carcinoma cells via enhancing cells stemness. ( 29959065 )
2018
26
Endoscopic Surgery for Delayed Sinonasal Complications of Radiation Therapy for Nasopharyngeal Carcinoma: A Subjective Outcome. ( 29439883 )
2018
27
LncRNA-LINC00460 facilitates nasopharyngeal carcinoma tumorigenesis through sponging miR-149-5p to up-regulate IL6. ( 28987345 )
2018
28
Stable knockdown of ZBTB7A promotes cell proliferation and progression in nasopharyngeal carcinoma. ( 29699474 )
2018
29
Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. ( 29431618 )
2018
30
Using the nasoseptal flap for reconstruction after endoscopic debridement of radionecrosis in nasopharyngeal carcinoma. ( 29336293 )
2018
31
Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. ( 29413277 )
2018
32
Retraction Note to: Differences in the expression profiles of claudin proteins in human nasopharyngeal carcinoma compared with non-neoplastic mucosa. ( 29940962 )
2018
33
MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition. ( 29427737 )
2018
34
Activation of SREBP1-mediated lipogenesis by the Epstein-Barr Virus-encoded LMP1 promotes cell proliferation and progression of nasopharyngeal carcinoma. ( 29968360 )
2018
35
Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe. ( 28857155 )
2018
36
Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy. ( 29439312 )
2018
37
Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution. ( 29046165 )
2018
38
Elevated antibodies against Epstein-Barr virus among individuals predicted to carry nasopharyngeal carcinoma susceptibility variants. ( 29975184 )
2018
39
Diffusion kurtosis imaging of a human nasopharyngeal carcinoma xenograft model: Initial experience with pathological correlation. ( 29221965 )
2018
40
The diagnosis and management of rare cystic liver metastases from nasopharyngeal carcinoma: A case report. ( 29952994 )
2018
41
Vimentin is a crucial target for anti-metastasis therapy of nasopharyngeal carcinoma. ( 28744809 )
2018
42
Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma. ( 29425953 )
2018
43
Functions and Roles of Long-Non-Coding RNAs in Human Nasopharyngeal Carcinoma. ( 29448252 )
2018
44
=Osteoradionecrosis of the Skull Base in Nasopharyngeal Carcinoma: Incidence and Risk Factors. ( 29960057 )
2018
45
Calycosin inhibits nasopharyngeal carcinoma cells by influencing EWSAT1 expression to regulate the TRAF6-related pathways. ( 29966979 )
2018
46
BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM. ( 29123267 )
2018
47
Functionalized Graphene Oxide as a nanocarrier of new Copper (II) complexes for targeted therapy on nasopharyngeal carcinoma. ( 29981404 )
2018
48
Association of the rs1760944 polymorphism in the APEX1 base excision repair gene with risk of nasopharyngeal carcinoma in a population from an endemic area in South China. ( 28464393 )
2018
49
Early evaluation of radiation-induced parotid damage in patients with nasopharyngeal carcinoma by T2 mapping and mDIXON Quant imaging: initial findings. ( 29422068 )
2018
50
Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma. ( 29973197 )
2018

Variations for Nasopharyngeal Carcinoma

ClinVar genetic disease variations for Nasopharyngeal Carcinoma:

6 (show top 50) (show all 58)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
2 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
3 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
4 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
5 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
6 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
7 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
8 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
9 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
10 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
11 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
12 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
13 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
14 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
15 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
16 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
17 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
18 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
19 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
20 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
21 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 GRCh38 Chromosome 1, 114713909: 114713909
22 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 NCBI36 Chromosome 1, 115058053: 115058053
23 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
24 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
25 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
26 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
27 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
28 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
29 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
30 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
31 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Uncertain significance rs138729528 GRCh38 Chromosome 17, 7675089: 7675089
32 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Uncertain significance rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
33 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
34 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
35 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
36 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 GRCh38 Chromosome 1, 114713907: 114713907
37 FGFR2 NM_000141.4(FGFR2): c.1645A> C (p.Asn549His) single nucleotide variant Likely pathogenic rs1057519045 GRCh37 Chromosome 10, 123258036: 123258036
38 FGFR2 NM_000141.4(FGFR2): c.1645A> C (p.Asn549His) single nucleotide variant Likely pathogenic rs1057519045 GRCh38 Chromosome 10, 121498522: 121498522
39 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
40 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
41 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
42 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
43 FGFR2 NM_000141.4(FGFR2): c.1647T> A (p.Asn549Lys) single nucleotide variant Likely pathogenic rs121913476 GRCh37 Chromosome 10, 123258034: 123258034
44 FGFR2 NM_000141.4(FGFR2): c.1647T> A (p.Asn549Lys) single nucleotide variant Likely pathogenic rs121913476 GRCh38 Chromosome 10, 121498520: 121498520
45 FGFR2 NM_022970.3(FGFR2): c.1917T> A (p.Asn639Lys) single nucleotide variant Likely pathogenic rs1057519854 GRCh37 Chromosome 10, 123247577: 123247577
46 FGFR2 NM_022970.3(FGFR2): c.1917T> A (p.Asn639Lys) single nucleotide variant Likely pathogenic rs1057519854 GRCh38 Chromosome 10, 121488063: 121488063
47 FGFR2 NM_000141.4(FGFR2): c.1642A> C (p.Ile548Leu) single nucleotide variant Likely pathogenic rs1057519901 GRCh37 Chromosome 10, 123258039: 123258039
48 FGFR2 NM_000141.4(FGFR2): c.1642A> C (p.Ile548Leu) single nucleotide variant Likely pathogenic rs1057519901 GRCh38 Chromosome 10, 121498525: 121498525
49 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
50 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh38 Chromosome 17, 7675089: 7675089

Cosmic variations for Nasopharyngeal Carcinoma:

9 (show top 50) (show all 817)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10659 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 32
2 COSM10656 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 32
3 COSM45589 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1037A>C p.E346A 17:7670672-7670672 32
4 COSM69404 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.994-1G>A p.? 17:7670716-7670716 32
5 COSM10943 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.841G>C p.D281H 17:7673779-7673779 32
6 COSM10790 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.455C>T p.P152L 17:7675157-7675157 32
7 COSM11354 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.991C>T p.Q331* 17:7673537-7673537 32
8 COSM10738 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.542G>A p.R181H 17:7675070-7675070 32
9 COSM44633 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.583A>T p.I195F 17:7674948-7674948 32
10 COSM10939 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 32
11 COSM10863 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.833C>T p.P278L 17:7673787-7673787 32
12 COSM43650 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.638G>T p.R213L 17:7674893-7674893 32
13 COSM87104 TET2 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.2474C>G p.S825* 4:105236416-105236416 32
14 COSM25844 STK11 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.647C>T p.S216F 19:1220630-1220630 32
15 COSM6212411 SPEN upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.2761C>T p.Q921* 1:15929001-15929001 32
16 COSM13115 SMAD4 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.431C>G p.S144* 18:51049301-51049301 32
17 COSM110698 SF3B1 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1997A>T p.K666M 2:197402636-197402636 32
18 COSM6908550 SETD2 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.2423G>A p.G808D 3:47120704-47120704 32
19 COSM1942416 RB1 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.2107-1G>C p.? 13:48463730-48463730 32
20 COSM22911 RB1 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.2104C>T p.Q702* 13:48459831-48459831 32
21 COSM5219 PTEN upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.388C>G p.R130G 10:87933147-87933147 32
22 COSM5312 PTEN upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.895G>T p.E299* 10:87960987-87960987 32
23 COSM23657 PTEN upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1015C>T p.P339S 10:87961107-87961107 32
24 COSM5078 PTEN upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.367C>T p.H123Y 10:87933126-87933126 32
25 COSM6945883 PMS2 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.571T>C p.Y191H 7:5999242-5999242 32
26 COSM6945882 PLK2 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1955C>G p.S652C 5:58454686-58454686 32
27 COSM775 PIK3CA upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.3140A>G p.H1047R 3:179234297-179234297 32
28 COSM763 PIK3CA upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 32
29 COSM746 PIK3CA upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.263G>A p.R88Q 3:179199088-179199088 32
30 COSM748 PIK3CA upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.317G>T p.G106V 3:179199142-179199142 32
31 COSM480344 PBRM1 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.2605C>T p.Q869* 3:52603695-52603695 32
32 COSM580 NRAS upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.181C>A p.Q61K 1:114713909-114713909 32
33 COSM6908552 NOTCH1 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1636G>T p.G546* 9:136516014-136516014 32
34 COSM6908565 MLH1 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.678-1G>A p.? 3:37014431-37014431 32
35 COSM422503 MED12 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.514G>C p.E172Q 23:71120131-71120131 32
36 COSM6908582 LRP1B upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.9035-1G>C p.? 2:140492694-140492694 32
37 COSM6908547 LRP1B upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.10347C>A p.C3449* 2:140442571-140442571 32
38 COSM3379786 LRP1B upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.4894C>T p.R1632* 2:140850147-140850147 32
39 COSM6982523 KMT2A upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.9438C>A p.F3146L 11:118505339-118505339 32
40 COSM96325 KEAP1 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.652G>C p.E218Q 19:10492250-10492250 32
41 COSM6982519 IFNGR1 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.546+2T>A p.? 6:137204330-137204330 32
42 COSM472251 GRIN2A upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1249G>A p.V417I 16:9849835-9849835 32
43 COSM715 FGFR3 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.746C>G p.S249C 4:1801841-1801841 32
44 COSM49174 FGFR2 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.289G>A p.A97T 10:121565525-121565525 32
45 COSM6908583 FBXW7 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1591G>T p.E531* 4:152326059-152326059 32
46 COSM22975 FBXW7 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1513C>T p.R505C 4:152326137-152326137 32
47 COSM22932 FBXW7 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1393C>T p.R465C 4:152328233-152328233 32
48 COSM6908556 FBXW7 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.74C>G p.S25* 4:152411730-152411730 32
49 COSM6908560 FAT1 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.6956C>G p.S2319* 4:186619630-186619630 32
50 COSM48360 ERBB3 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.850G>A p.G284R 12:56088138-56088138 32

Copy number variations for Nasopharyngeal Carcinoma from CNVD:

7 (show all 41)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72234 12 7764270 8036678 Duplication CLEC4C Nasopharyngeal cancer
2 72235 12 7764270 8036678 Duplication NANOG Nasopharyngeal cancer
3 72236 12 7764270 8036678 Duplication NANOGNB Nasopharyngeal cancer
4 72237 12 7764270 8036678 Duplication SLC2A14 Nasopharyngeal cancer
5 72238 12 7764270 8036678 Duplication SLC2A3 Nasopharyngeal cancer
6 126614 19 19848080 20497256 Deletion MIR1270-1 Nasopharyngeal cancer
7 126615 19 19848080 20497256 Deletion MIR1270-2 Nasopharyngeal cancer
8 126616 19 19848080 20497256 Deletion ZNF253 Nasopharyngeal cancer
9 126617 19 19848080 20497256 Deletion ZNF486 Nasopharyngeal cancer
10 126618 19 19848080 20497256 Deletion ZNF682 Nasopharyngeal cancer
11 126619 19 19848080 20497256 Deletion ZNF826P Nasopharyngeal cancer
12 126620 19 19848080 20497256 Deletion ZNF90 Nasopharyngeal cancer
13 126621 19 19848080 20497256 Deletion ZNF93 Nasopharyngeal cancer
14 132647 19 59423491 59445355 Deletion LILRA6 Nasopharyngeal cancer
15 171484 3 168801287 168851758 Amplification EVI1 Nasopharyngeal cancer
16 171493 3 168867391 169381563 Amplification MDS1 Nasopharyngeal cancer
17 177937 3 65166887 65190844 Deletion Nasopharyngeal cancer
18 197433 5 176843000 176857208 Deletion LMP1 Nasopharyngeal cancer
19 205127 6 121025447 121050579 Deletion Nasopharyngeal cancer
20 210827 6 31463047 31563588 Deletion HCG26 Nasopharyngeal cancer
21 210828 6 31463047 31563588 Deletion HCP5 Nasopharyngeal cancer
22 210829 6 31463047 31563588 Deletion MICA Nasopharyngeal cancer
23 210832 6 31463297 31559455 Deletion HCG26 Nasopharyngeal cancer
24 210836 6 31463297 31559455 Deletion HCP5 Nasopharyngeal cancer
25 210840 6 31463297 31559455 Deletion MICA Nasopharyngeal cancer
26 212636 6 4007991 32935606 Deletion LMP2 Nasopharyngeal cancer
27 220654 7 140736 180194 Duplication CCDC146 Nasopharyngeal cancer
28 220655 7 140736 180194 Duplication LOC100132832 Nasopharyngeal cancer
29 220656 7 140736 180194 Duplication LOC100133091 Nasopharyngeal cancer
30 220657 7 140736 180194 Duplication PMS2L11 Nasopharyngeal cancer
31 220658 7 140736 180194 Duplication POMZP3 Nasopharyngeal cancer
32 222456 7 152200000 154700000 Duplication Nasopharyngeal cancer
33 222457 7 152200000 154700000 Duplication Nasopharyngeal cancer
34 222532 7 153118877 153284978 Duplication Nasopharyngeal cancer
35 222533 7 153118877 153284978 Duplication Nasopharyngeal cancer
36 224029 7 2721151 3758564 Duplication CARD11 Nasopharyngeal cancer
37 224030 7 2721151 3758564 Duplication GNA12 Nasopharyngeal cancer
38 227304 7 66680598 66860844 Deletion AR Nasopharyngeal cancer
39 229234 7 892539 3753994 Duplication Nasopharyngeal cancer
40 236340 8 15447307 15475846 Deletion TUSC3 Nasopharyngeal cancer
41 256863 9 9780222 9786577 Deletion Nasopharyngeal cancer

Expression for Nasopharyngeal Carcinoma

Search GEO for disease gene expression data for Nasopharyngeal Carcinoma.

Pathways for Nasopharyngeal Carcinoma

Pathways related to Nasopharyngeal Carcinoma according to KEGG:

37
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

Pathways related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 HRAS NFKBIA NRAS PIK3CA TP53
2 12.79 HRAS NFKBIA NRAS PIK3CA TP53
3
Show member pathways
12.75 HRAS NFKBIA NRAS PIK3CA TP53
4
Show member pathways
12.64 HRAS NFKBIA NRAS PIK3CA TP53
5
Show member pathways
12.62 HRAS NFKBIA NRAS PIK3CA TP53
6
Show member pathways
12.47 HRAS NRAS PIK3CA TP53
7
Show member pathways
12.47 HRAS NFKBIA NRAS PIK3CA TP53
8
Show member pathways
12.45 HRAS NFKBIA NRAS PIK3CA
9
Show member pathways
12.45 HRAS NRAS PIK3CA TP53
10
Show member pathways
12.41 HRAS NFKBIA NRAS PIK3CA
11
Show member pathways
12.38 HRAS NFKBIA NRAS PIK3CA
12
Show member pathways
12.38 HRAS NFKBIA NRAS PIK3CA
13
Show member pathways
12.38 HRAS NFKBIA NRAS PIK3CA TP53
14
Show member pathways
12.34 HRAS NFKBIA PIK3CA TP53
15
Show member pathways
12.31 HRAS NFKBIA NRAS PIK3CA
16
Show member pathways
12.25 HRAS NFKBIA PIK3CA TP53
17
Show member pathways
12.25 HRAS NFKBIA NRAS PIK3CA
18 12.2 HRAS NRAS PIK3CA TP53
19
Show member pathways
12.19 HRAS NFKBIA NRAS PIK3CA TP53
20
Show member pathways
12.18 HRAS NFKBIA NRAS TP53
21
Show member pathways
12.16 HRAS NRAS PIK3CA TP53
22 12.13 HRAS NFKBIA NRAS PIK3CA TP53
23
Show member pathways
12.11 HRAS NFKBIA NRAS PIK3CA
24
Show member pathways
12.09 HRAS NFKBIA NRAS PIK3CA
25 12.06 HRAS NRAS PIK3CA TP53
26
Show member pathways
12.06 HRAS NRAS PIK3CA TP53
27 12.04 HRAS NRAS PIK3CA TP53
28
Show member pathways
12 HRAS NFKBIA NRAS PIK3CA
29
Show member pathways
11.99 HRAS NRAS PIK3CA TP53
30 11.96 HRAS NFKBIA NRAS PIK3CA TP53
31 11.93 HRAS NRAS TP53
32
Show member pathways
11.92 HRAS NRAS PIK3CA
33 11.91 HRAS MIR100 MIR29C NRAS PIK3CA TP53
34 11.87 HRAS NRAS PIK3CA
35 11.85 HRAS NRAS PIK3CA TP53
36 11.83 NFKBIA PIK3CA TP53
37
Show member pathways
11.82 HRAS NRAS PIK3CA
38 11.82 HRAS NRAS PIK3CA TP53
39
Show member pathways
11.81 HRAS NRAS PIK3CA
40 11.79 HRAS NRAS PIK3CA TP53
41
Show member pathways
11.74 HRAS NRAS PIK3CA
42 11.67 HRAS NRAS TP53
43 11.62 HRAS PIK3CA TP53
44 11.6 HRAS NRAS TP53
45 11.27 HRAS NRAS TP53
46 11.27 HRAS NRAS PIK3CA TP53
47
Show member pathways
11.16 HRAS NFKBIA PIK3CA
48 11.14 HRAS NFKBIA NRAS PIK3CA TP53
49 11.06 HRAS NRAS PIK3CA
50 10.97 HRAS PIK3CA

GO Terms for Nasopharyngeal Carcinoma

Biological processes related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 8.8 HRAS NRAS TP53

Sources for Nasopharyngeal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....